Related Experiment Video
Updated: Jun 23, 2026
08:32
Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Endothelial nitric oxide synthase gene polymorphisms are not associated with recurrent aphthous stomatitis
Jumana A Karasneh1, Reza Baszrafshani, Martin Thornhill
1Department of Oral Medicine & Oral Surgery, Dental School, Jordan University of Science & Technology, PO Box 3030, Irbid, Jordan. jumana2003@yahoo.com
Archives of Oral Biology
|May 5, 2009
Summary
Endothelial nitric oxide synthase (eNOS) gene variations are not linked to recurrent aphthous stomatitis (RAS). This suggests different genetic causes for oral ulcers in RAS compared to Behçet's disease (BD).
Area of Science:
- Genetics
- Immunology
- Oral Medicine
Background:
- Recurrent aphthous stomatitis (RAS) is a common oral mucosal disease.
- Oral ulceration is a key feature of Behçet's disease (BD).
- Endothelial nitric oxide synthase (eNOS) gene polymorphisms have been associated with BD.
Purpose of the Study:
- To investigate the association between eNOS gene polymorphisms and RAS.
- To determine if genetic factors underlying BD are also involved in RAS.
Main Methods:
- A case-control study involving 91 RAS patients and 91 healthy controls.
- Genotyping for eNOS -786 and +894 single nucleotide polymorphisms (SNPs) and a VNTR polymorphism.
- Comparison of allele and genotype frequencies using Chi-square analysis.
Main Results:
- No significant differences in allele or genotype frequencies for the studied eNOS polymorphisms were observed between RAS patients and controls.
- The investigated eNOS gene variations are not associated with recurrent aphthous stomatitis.
Conclusions:
- The genetic factors associated with Behçet's disease, specifically eNOS polymorphisms, do not appear to play a role in recurrent aphthous stomatitis.
- The common oral ulceration in RAS and BD may stem from distinct genetic etiologies.
- While eNOS gene polymorphisms are not linked to RAS, nitric oxide's involvement via other pathways, such as inducible nitric oxide synthase (iNOS), remains possible.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...